n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, June 9th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Windtree Therapeutics, Inc. (WINT)

Trader Power News and MarketClub Analysis reported earlier on Windtree Therapeutics, Inc. (WINT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Windtree Therapeutics, Inc. is a biotechnology company concentrating on developing aerosolized KL4 surfactant therapies for respiratory diseases. It is initially focusing on improving the management of respiratory distress syndrome (RDS) in premature infants. A clinical-stage biotechnology enterprise, Windtree Therapeutics is based in Warrington, Pennsylvania.

The Company’s proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant), which is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies undergoing development to enable non-invasive administration of aerosolized KL4 surfactant. Windtree believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address an assortment of respiratory diseases for which there are few or no approved therapies.

Regarding KL4 Surfactant, the Company’s KL4 surfactant technology produces a synthetic surfactant structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 (sinapultide). This is a 21-amino acid peptide designed to imitate the essential attributes of the human surfactant protein B (SP-B). SP-B is one of four known surfactant proteins. It is the most important for proper functioning of the respiratory system.

Concerning its Aerosol Delivery System (ADS) Technology Platform, the design of Windtree Therapeutics’ proprietary ADS is to aerosolize KL4 surfactant. An aerosol is created by pumping KL4 surfactant through a heated capillary, subsequently, the aerosol cools and slows in velocity. It yields a dense aerosol with a defined particle size suitable for respiration.

In May, Windtree Therapeutics announced that it was awarded $0.9 million under an earlier announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to $2.6 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support the AEROSURF® Phase 2b clinical trial in respiratory distress syndrome (RDS). Windtree was awarded an initial $1.0 million under this grant in August of 2016. Over the next year, it may be awarded up to an additional $0.7 million through the completion of the Phase 2b clinical trial and one-year patient follow-up.

AEROSURF is a novel, investigational drug/device combination product. It combines the Company’s proprietary KL4 surfactant and aerosolization technologies. AEROSURF is undergoing development to potentially decrease or eliminate the need for endotracheal intubation and mechanical ventilation in the treatment of premature infants with respiratory distress syndrome (RDS). 

Last week, Windtree Therapeutics announced completion of enrollment in its AEROSURF® Phase 2b clinical trial evaluating aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants, 28 to 32-week gestational age, receiving nasal continuous positive airway pressure (nCPAP) for RDS. A total of 221 patients have been enrolled at 52 sites in North America, Europe, and Latin America. Windtree Therapeutics reaffirms its plan to announce top-line results for the trial next month.

Windtree Therapeutics, Inc. (WINT), closed Friday's trading session at $0.85, down 2.43%, on 16,105 volume with 24 trades. The average volume for the last 60 days is 63,783 and the stock's 52-week low/high is $0.60/$4.42.

Cerebain Biotech Corp. (CBBT)

Viral Stocks, Wall Street Mover, and Greenbackers reported earlier on Cerebain Biotech Corp. (CBBT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cerebain Biotech Corp. concentrates on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. A development-stage medical device enterprise, the Company previously went by the name Discount Dental Materials, Inc. It changed its name to Cerebain Biotech Corp. in June of 2014. Cerebain Biotech has its corporate headquarters in Costa Mesa, California.

The Company’s device takes advantage of the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. Its patent-pending device is implanted in the omentum.

The omentum is a protective layer of skin that protects the abdominal organs. The design of the device is to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.

Cerebain Biotech’s technology has allowed for the development of a medical device that can be implanted using a minimally invasive procedure. Upon implantation, through what will most likely be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

The Company’s intention is to seek Food and Drug Administration (FDA) approval in tandem with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. Cerebain has reached a decisive point in its research and is planning to begin development of the device. It has signed a Memorandum of Understanding (MOU) with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the MOU is to begin testing of Cerebain Biotech’s Medical Device upon completion of development.

Present plans for Cerebain include allocating resources to facilitate its FDA strategy as it relates to further research and testing of its existing technology. Additionally, plans include designing a surgical manual to be used by doctors and clinicians for implanting Cerebain’s medical device. The Company will also provide additional administrative and financial support to its scientists to leverage their time to advance Cerebain’s technologies as it nears clinical trials.

In February of this year, Cerebain Biotech announced that it engaged a Biotechnical Engineer to serve on the corporate team. This engagement comes as Cerebain prepares itself for clinical trials and the FDA application process in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. The Company engaged the Biotechnical Engineer to support Sonos Models, Inc. as it continues the development of Cerebain Biotech’s Medical Device Product for the treatment of Alzheimer’s.

Cerebain Biotech Corp. (CBBT), closed Friday's trading session at $0.42, up 13.51%, on 25,000 volume with 5 trades. The average volume for the last 60 days is 3,279 and the stock's 52-week low/high is $0.175/$1.24.

Wizard World, Inc. (WIZD)

Wall Street Resources and TopPennyStockMovers reported earlier on Wizard World, Inc. (WIZD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Wizard World, Inc. is the foremost provider of multiple Comic Cons and pop culture conventions around the world. It produces Comic Cons (live multimedia conventions) and pop culture conventions. These celebrate pop-fi, pop culture, movies, television, cosplay, comics, graphic novels, toys, video gaming, sci-fi, gaming, original art, collectibles, contests and more. Wizard World is headquartered in El Segundo, California.  

Wizard World’s Comic Cons provide sales, marketing, promotions, public relations, advertising, and sponsorship opportunities for entertainment companies, toy companies, gaming companies, publishing companies, marketers, corporate sponsors, and retailers. Wizard World Digital, its online publication, covers new and upcoming products and talents in the pop culture world. Wizard World’s events often feature celebrities from movies and TV, artists and writers, and events such as premieres, gaming tournaments, panels, and costume contests.

Wizard World has its ComicConBox™. This is a subscription-based premium monthly box service. It provides fans the opportunity to receive exclusive collectibles, toys, technology, games, licensed artwork, comics, apparel, Wizard World Comic Con tickets, VIP discounts and more, delivered to their doors.

Additionally, the Company has its CONtv. This is a subscription-based digital service. It brings fans their favorite films, TV series, comics, behind the scenes access to Wizard World Comic Cons, and more. CONtv provides consumers access to thousands of hours of exclusive content highlighting an original slate of programming and an extensive digital catalog of more than 1,200 titles. Moreover, Wizard World has launched the new music concert series, and the Wizard World Store.

In January 2017, Wizard World announced the establishment of a new SocialCon™ Operating Unit within Wizard World. SocialCon™ will produce a series of conventions. These will feature meet-and-greets, live performances, Q&A panels, autographs, photo ops and more with many of today’s most-followed social media influencers.

Mr. Mike Abrams, Founder and Chief Executive Officer of KLiK events (a major producer of social media tours and events) who joined Wizard World as Senior Vice President of Social Media programming leads SocialCon™.

Recently, Wizard World announced the addition of entertainment industry veterans Mr. Michael Breen and Mr. Jordan Schur to its Board of Directors. Mr. Breen is an English qualified solicitor. He was previously the Managing Director of the Sports and Entertainment Division of Bank Insinger de Beaufort N.V. -  a wealth management organization that is part of the BNP Paribas Group.

Mr. Schur is a veteran of the music and film industries. He has a reputation for creating and overseeing innovative and highly profitable ventures. Mr. Schur's first major success was Flip Records.

Wizard World, Inc. (WIZD), closed Friday's trading session at $0.20, up 5.68%, on 13,100 volume with 6 trades. The average volume for the last 60 days is 15,571 and the stock's 52-week low/high is $0.1245/$0.53.

Quest Solution, Inc. (QUES)

Stock News Now reported previously on Quest Solution, Inc. (QUES), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quest Solution, Inc. is a Specialty Systems Integrator centered on Field and Supply Chain Mobility. The Company specializes in the design, deployment, and management of enterprise mobility solutions. These include Automatic Identification (AIDC), Mobile Cloud Analytics, RFID (Radio Frequency Identification) and proprietary Mobility software. Quest Solution earlier completed a merger with ViascanQdata. This merger adds major labels and ribbons manufacturing capacity. Quest Solution is based in Eugene, Oregon, and has offices across the U.S.

Additionally, the Company is a manufacturer and distributor of consumables (labels, tags, and ribbons), RFID solutions, and barcoding printers. The design of its mobility products and services offering is to identify, track, trace, share and connect data to enterprise systems. These include CRM or ERP solutions. Quest’s customers are leading Fortune 500 companies from many sectors, including manufacturing, retail, distribution, food/beverage, transportation and logistics, health care, and chemicals/gas/oil.

Quest Solution has its partnership with TrackX, Inc., a foremost provider of RFID-enabled asset tracking and supply chain management solutions. TrackX's AssetTrack platform incorporates workflow processing, event management, and strong analytics to deliver solutions across an increasing number of industries. The partnership between Quest Solution and TrackX represents the next trend in solutions within the Industrial Internet of Things where man-to machine and machine-to-machine interaction is taking place on a much larger worldwide scale.

Quest Solution provides its clients with a complete suite of professional services. These include IT project management; mobility assessment; wireless site survey; and wireless LAN installation. Services also include staging; onsite system integration testing; system and user documentation; and custom training and compliance.

Quest Solution will deploy configured and customized off-the-shelf software. It will also deploy custom-developed applications tailored to a client’s business environment. In addition, the Company’s experts will ensure compatibility with hardware and existing solutions, and guide clients through installation, integration, and deployment. Quest Solution offers a complete set of bar code and mobility equipment. These support cost-effective operations and employee productivity.

In May, Quest Solution announced that it has worked with TrackX Holdings (TKXHF) to launch Phase 1 of an RFID asset tracking and management solution for a top online used car retailer. The integrated solution is responsible for tracking and managing hundreds of thousands of vehicles throughout all the customer's U.S. locations. The solution integrates predictive analytics and workflow processing to efficiently manage their automotive inventory. Quest Solution's essential role in Phase 1 of a multi-phased project supported TrackX's delivery of its Global Asset Management for Enterprise (GAME) solution to this fast-growing customer.

Quest Solution, Inc. (QUES), closed Friday's trading session at $0.117, even for the day, on 139 volume with 4 trades. The average volume for the last 60 days is 24,723 and the stock's 52-week low/high is $0.001/$0.18.

AmpliTech Group, Inc. (AMPG)

AllPennyStocks, SmallCapVoice, PennyStocks24, Information Solutions Group, Pumps and Dumps, Trading Wall St, fusionspicks, Jet-Life Penny Stocks, OTCMagic, Penny Stock Gainers, RockingPennyStocks, Wallstreetbuzz, Ascending Stocks, BestStocksDaily, HoleinOneStocks.net, HotStockProfits, and Fortune Penny Stocks reported on AmpliTech Group, Inc. (AMPG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF Low Noise Amplifiers (LNA) and Power Amplifiers (PA). These are for the domestic and global, SATCOM, Space, and Military markets. In addition, the Company provides consulting services to help with any microwave components or systems design problems. AmpliTech sells its products by way of sales representatives and distributors in North America, Europe, and Asia. AmpliTech Group is based in Bohemia, New York and the Company lists on the OTC Markets Group’s OTCQB.

Mr. Fawad Maqbool founded AmpliTech Group to fill the need for high quality, reliable, state-of-the-art, RF components at an affordable cost, with quick deliveries, and trouble-free customer service. Mr. Maqbool has greater than 20 years of experience in the design of microwave amplifiers and components.

The Company’s designs cover the frequency spectrum from 50 kHz to 40 GHz - eventually providing designs up to 100 GHz. AmpliTech can provide complex, custom solutions for almost any custom requirements presented to it. It can provide contract assembly of customers' own designs.     

AmpliTech Group provides its customers with consulting services for their system development. In addition, the Company provides technical assistance in integration and packaging technologies and microwave sub-systems and amplifier related sub-assemblies.

AmpliTech utilizes the most up-to-date CAD microwave simulation technology to design and develop from concept to final manufacture of a deliverable product with first-class accuracy. The Company expects to release new products targeted at the wireless and satellite markets, which will provide advanced technology and performance.

In May, AmpliTech Group announced an update to report fiscal results of Q1 of 2017. It reported Q1 Revenue of $458,600 with Net Income of $33,664. The Company introduced two new Power Amplifier Products for wireless and military applications in the quarter.

AmpliTech had a Sales increase of $312,120 or 213 percent from the same time last year. It had a corresponding increase in Gross Profit of 579 percent and an overall increase in Net Income of $173,577.

AmpliTech Group, Inc. (AMPG), closed Friday's trading session at $0.0725, up 3.57%, on 29,500 volume with 7 trades. The average volume for the last 60 days is 72,253 and the stock's 52-week low/high is $0.0199/$0.11.

graphic

The QualityStocks
Company Corner

graphic
graphic

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.02, up 1.90%, on 24,061 volume with 42 trades. The stock’s average daily volume over the past 60 days is 66,490 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing ChineseInvestors.com Inc. (OTCQB: CIIX) and its recent expansion into the multi-billion dollar legal hemp industry. Please follow the link to read the full article: http://www.cannabisfn.com/chineseinvestors-com-ciix-edge-lucrative-hemp-oil-industry/

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com Has an Edge in Lucrative Hemp Oil Industry -- CFN Media

ChineseInvestors.com, Inc. Engages Venture Building Firm 'Launch Haus, LLC' to Drive its Hemp-based eCommerce and Network Marketing Business Divisions

ChineseInvestors.com, Inc. to Attend 6th Annual SeeThru Equity Microcap Investor Conference

Ethema Health Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight Ethema Health Corp. (GRST). Today, Ethema Health Corp. closed trading at $0.06375, up 30.10%, on 15,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 16,904, and its 52-week low/high is $0.015/$0.083.

Ethema Health Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.

More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the Ethema Health approach differentiates itself in a number of ways:

  • Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
  • Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.

In addition to his experience with Ethema Health, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer

Ethema Health Corp. Company Blog

Ethema Health Corp. News:

Ethema Health Engages NetworkNewsWire for Corporate Communications Solutions

Ethema Health Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

Ethema Health Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.291, up 22.58%, on 561,285 volume with 244 trades. The stock’s average daily volume over the past 60 days is 1,038,531, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.1276, up 14.44%, on 10,970,542 volume with 970 trades. The stock’s average daily volume over the past 60 days is 2,609,129, and its 52-week low/high is $0.0023/$0.1315.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.

WeedTV.com

WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network, Inc. CEO Featured on MoneyTV with Donald Baillargeon, 6/2

Player's Network, Inc. Subsidiary Awarded Two Nevada Recreational Marijuana Licenses

Player's Network Subsidiary Awarded Medical Marijuana Licenses

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.468, even for the day. The stock’s average daily volume over the past 60 days is 3,458, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Signs Binding Letter of Intent to Acquire W Marketing

ProBility Media Corp. Expands Distribution with New 2017 Electrician Exam Preparation Series

ProBility Media Corp. Appoints Billy Smith to the Newly Created Vocational Advisory Board

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

ProTrader
(MUSS) +592.31%

2.

PHUB News
(DCTH) +48.10%

3.

Fortune Stock Alerts
(CHRO) +31.07%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251